{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-218004","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.571318+00:00","generated_at":"2026-06-24T00:54:08.890768+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Verrica Q2 net loss $10.2M; plans VP-102 NDA resubmission in Q1 2023","bullets":["Q2 2022 net loss $10.2M ($0.37 GAAP EPS); non-GAAP net loss $8.8M ($0.32/share).","License revenue $0.2M from Torii; R&D $4.2M, G&A $5.2M.","Held Type A FDA meeting; began working with Piramal for VP-102 bulk solution.","Raised $28.5M gross in July 2022 public offering at $2.10/share.","Cash, equivalents, marketable securities, restricted cash $54.4M as of June 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-218004","json":"https://secwatch.observer/filing/0001193125-22-218004.json","markdown":"https://secwatch.observer/filing/0001193125-22-218004.md","text":"https://secwatch.observer/filing/0001193125-22-218004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312522218004/0001193125-22-218004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312522218004/d358754d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:54:08.890768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}